We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.00 | 2.40 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMODX
RNS Number : 8169A
Omega Diagnostics Group PLC
29 March 2017
Omega Diagnostics Group PLC
("Omega" or the "Company")
VISITECT(R) Malaria CE-Mark and successful Indian FDA inspection
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has CE-Marked its VISITECT(R) range of Malaria tests comprising:
-- VISITECT(R) Malaria Pf (detection of HRP2 antigen in P. falciparum)
-- VISITECT(R) Malaria Pf/PAN (detection of P. falciparum, non-P. falciparum or mixed infections)
-- VISITECT(R) Malaria Pf/Pv (detection and differentiation of P. falciparum and P. vivax)
The successful completion of the verification and validation programme means these tests, manufactured in our facility in Pune, India are available for general sale through business to business channels in those countries which do not require individual product registration. We anticipate achieving additional regulatory approvals within the next 12 months to enable the Company to participate in higher volume tender business.
In addition, the Company confirms that its manufacturing facility in Pune has successfully undergone an annual inspection from the Indian FDA, confirming the facility is compliant with GMP processes for manufacturing, testing, storage and QA processes and that its Manufacturing Licence is valid until January 2021.
Andrew Shepherd, Chief Executive Officer of the Company commented: "This milestone demonstrates our continuing investment in people and infrastructure is beginning to bear fruit. Whilst we expect relatively modest sales during the next financial year to 31 March 2018, we anticipate generating significant demand from the subsequent financial year onwards with high quality products at affordable prices which are both crucial for commercial success."
Contacts:
Omega Diagnostics Group Tel: 01259 763 030 PLC Andrew Shepherd, Chief www.omegadiagnostics.com Executive Kieron Harbinson, Group Finance Director Jag Grewal, Group Sales and Marketing Director finnCap Ltd Tel: 020 7220 0500 Geoff Nash/James Thompson (Corporate Finance) Mia Gardner (Corporate Broking) Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com Paul McManus Mob: 07980 541 893 Lianne Cawthorne Mob: 07584 391 303
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAEDPADSXEAF
(END) Dow Jones Newswires
March 29, 2017 02:01 ET (06:01 GMT)
1 Year Omega Diagnostics Chart |
1 Month Omega Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions